Meeting
2019 ASCO Annual Meeting
Efficacy and safety of CAR19/22 t-cell “cocktail” therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma.
Authors
Liang Huang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Liang Huang , Na Wang , Chunrui Li , Yi Xiao , Yang Cao , Min Xiao , Yicheng Zhang , Tongcun Zhang , Jianfeng Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
ChiCTR-OPN-16008526
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2534)
DOI
10.1200/JCO.2019.37.15_suppl.2534
Abstract #
2534
Poster Bd #
178
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL).
First Author: Frederick L. Locke
Poster
2023 ASCO Annual Meeting
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).
First Author: Nicholas Stong
Poster
2023 ASCO Annual Meeting
Reduction in Curie score in neuroblastoma patients treated with naxitamab.
First Author: Jaume Mora
Poster
2022 ASCO Annual Meeting
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Don A. Stevens